- Home
- Análise grátis de aplicativos
- CV Risk Calc
- CV Risk Calc Vs. CardioRisk Calculator
CV Risk Calc vs CardioRisk Calculator Uso e estatísticas
A cardiac risk calculator is a very simple application that allows a cardiovascular risk calculation based on some user input parameters.
It calculates the following outcomes:
- 10 Years Risk.
This application has been provided with the hope that it will be useful, but without warranty, implied or explicit, of fitness for a particular purpose. The author will not accept responsibility for anything.
- Apple App Store
- Gratuitos
- Saúde e fitness
Ranking da Loja
- -
CardioRisk Calculator™ simplifies cardiovascular risk stratification and is a Canadian dyslipidemia guidelines application.
CardioRisk Calculator™ provides:
-quick calculations on % LDL-C reductions
-concise drug dosage information
-clear snapshot of a patient's CV risk
-options to bring lipid levels to target
-easy identification of familial hypercholesterolemia
This application has been developed with the ultimate goal of educating physicians on the most recent Canadian dyslipidemia guidelines and guidelines for the diagnosis of familial hypercholesterolemia.
Programming support for the CardioRisk Calculator™ was provided through unrestricted grants to support the CardioRisk Clinic from the following (in alphabetical order):
- Amgen Canada
- Bayer Inc
- Boehringer Ingelheim (Canada) Ltd
- FH Canada
- HLS Therapeutics
- Janssen Inc
- Novo Nordisk Canada
- Sanofi Canada
- Apple App Store
- Gratuitos
- Médico
Ranking da Loja
- -
CV Risk Calc versus CardioRisk Calculator comparação de classificação
Compare a tendência de classificação de CV Risk Calc nos últimos 28 dias versus CardioRisk Calculator
Classificação
Nenhum dado disponível
Comparação da classificação de CV Risk Calc vs. CardioRisk Calculator por país
Compare a tendência de classificação de CV Risk Calc nos últimos 28 dias versus CardioRisk Calculator
Nenhum dado para exibir
Faça comparações com qualquer site com o nosso teste grátis
janeiro 20, 2026